Alnylam Pharmaceuticals annual gross margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Alnylam Pharmaceuticals Gross Margin Growth & History (ALNY)
Alnylam Pharmaceuticals's gross margin was 81.77% for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 81.77% | −4.60 pp |
| 2024 | 2024-12-31 | 86.37% | +1.04 pp |
| 2023 | 2023-12-31 | 85.33% | −1.16 pp |
| 2022 | 2022-12-31 | 86.49% | +0.11 pp |
| 2021 | 2021-12-31 | 86.38% | +1.43 pp |
| 2020 | 2020-12-31 | 84.95% | −3.65 pp |
| 2019 | 2019-12-31 | 88.60% | −9.00 pp |
| 2018 | 2018-12-31 | 97.59% | −2.41 pp |
| 2017 | 2017-12-31 | 100.00% | — |
Alnylam Pharmaceuticals quarterly gross margin
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 76.90% | −4.75 pp |
| Q1 2026 | 2026-03-31 | 81.91% | −6.28 pp |
| Q4 2025 | 2025-12-31 | 75.60% | −7.10 pp |
| Q3 2025 | 2025-09-30 | 84.21% | +0.58 pp |
| Q2 2025 | 2025-06-30 | 81.64% | −8.16 pp |
| Q1 2025 | 2025-03-31 | 88.19% | −0.76 pp |
| Q4 2024 | 2024-12-31 | 82.69% | −0.94 pp |
| Q3 2024 | 2024-09-30 | 83.63% | −5.78 pp |
| Q2 2024 | 2024-06-30 | 89.80% | +13.44 pp |
| Q1 2024 | 2024-03-31 | 88.95% | +1.93 pp |
| Q4 2023 | 2023-12-31 | 83.63% | −2.59 pp |
| Q3 2023 | 2023-09-30 | 89.41% | +3.22 pp |
| Q2 2023 | 2023-06-30 | 76.37% | −8.49 pp |
| Q1 2023 | 2023-03-31 | 87.02% | −1.98 pp |
| Q4 2022 | 2022-12-31 | 86.22% | −0.77 pp |
| Q3 2022 | 2022-09-30 | 86.19% | +1.16 pp |
| Q2 2022 | 2022-06-30 | 84.86% | −1.42 pp |
| Q1 2022 | 2022-03-31 | 89.00% | +1.97 pp |
| Q4 2021 | 2021-12-31 | 86.99% | +0.31 pp |
| Q3 2021 | 2021-09-30 | 85.03% | +1.58 pp |
| Q2 2021 | 2021-06-30 | 86.28% | +3.85 pp |
| Q1 2021 | 2021-03-31 | 87.03% | +0.41 pp |
| Q4 2020 | 2020-12-31 | 86.68% | +3.66 pp |
| Q3 2020 | 2020-09-30 | 83.45% | −9.11 pp |
| Q2 2020 | 2020-06-30 | 82.43% | −7.89 pp |
| Q1 2020 | 2020-03-31 | 86.63% | −3.32 pp |
| Q4 2019 | 2019-12-31 | 83.01% | — |
| Q3 2019 | 2019-09-30 | 92.56% | −0.82 pp |
| Q2 2019 | 2019-06-30 | 90.33% | — |
| Q1 2019 | 2019-03-31 | 89.95% | — |
| Q3 2018 | 2018-09-30 | 93.38% | — |
Alnylam Pharmaceuticals gross margin trends
Over the last five fiscal years, Alnylam Pharmaceuticals's gross margin decreased from 84.95% to 81.77%, a change of −3.18 percentage points. The latest reported quarter, Q2 2026, shows 76.90%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗Community posts
Alnylam’s product sales jump 52% as it enlarges a pivotal heart-disease trial
Alnylam ($ALNY) reported third-quarter 2026 product revenue of $1.29 billion, up 52%, led by Amvuttra and Onpattro’s combined $1.15 billion contribution. Total revenue increased a slower 17% to $1.46 billion because collaboration revenue de ...
